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Abstract: We investigated the effectiveness and safety of direct oral anticoagulants (DOACs) for
secondary prevention in patients with atrial fibrillation (AF), particularly focusing on subgroups
of patients with severe, disabling, and recent stroke. Using the Korean National Health Insurance
Service claims database between January 2010 and April 2018, we selected OAC-naïve patients with
non-valvular AF and a history of stroke. Cumulative risks for recurrent stroke, major bleeding,
composite outcome (recurrent stroke + major bleeding), and mortality were compared between
DOAC and warfarin groups. Among 61,568 patients, 28,839 and 32,729 received warfarin and DOACs,
respectively. Compared with warfarin, DOACs were associated with lower risks of recurrent stroke
(hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.62–0.72), major bleeding (HR 0.73, 95% CI
0.66–0.80), composite outcome (HR 0.69, 95% CI 0.65–0.73), and mortality. DOAC use resulted in a
consistent trend of improved outcomes in the subgroups of patients with severe, disabling, and recent
stroke. In conclusion, DOACs were associated with lower risks of recurrent stroke, major bleeding,
composite clinical outcomes, and mortality in patients with AF and a history of stroke. These results
were consistent across all types of DOACs and subgroups of patients with severe, disabling, and
recent stroke.
Keywords: atrial fibrillation; anticoagulants; stroke; secondary prevention
1. Introduction
Atrial fibrillation (AF) is a major risk factor for stroke. Compared to other causes, strokes caused
by AF are usually more disabling and fatal [1]. Therefore, oral anticoagulation therapy (OAC) is
essential for the prevention of stroke in patients with AF [2,3]. Among patients with AF, those with
a history of stroke are categorized as a high-risk group, with a higher risk of recurrent stroke and
bleeding events [4]; therefore, optimal antithrombotic therapy is imperative in these patients.
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Previous pivotal randomized clinical trials (RCTs) that investigated a varied number of patients
with AF and a history of stroke reported that following subgroup analysis, the efficacy and safety profile
of direct oral anticoagulants (DOACs) was comparable or better than that of warfarin [5–8]. However,
most patients with severe, disabling, or recent stroke were excluded from the aforementioned RCTs;
therefore, limited data are available in this high-risk population. A recent retrospective observational
study reported that DOACs showed similar results with their respective RCT subgroup analysis in
patients with a history of stroke or transient ischemic attack [9]. However, the results had a limitation
because of the small sample size of the study. Moreover, there is a paucity of evidence regarding
secondary prevention in Asian patients, who are reportedly at a higher risk of intracranial bleeding [10].
In this large nationwide population-based study, we investigated the effectiveness and safety
of all four available DOACs (rivaroxaban, dabigatran, apixaban, and edoxaban) compared with that
of warfarin in Asian patients with non-valvular AF and a history of stroke, particularly focusing on
subgroups of patients with severe, disabling, and recent stroke.
2. Materials and Methods
Clinical data of the study population were obtained from the national health claims database
established by the National Health Insurance Service (NHIS) of Korea. The NHIS is a mandatory
universal health insurance service that provides comprehensive medical care to the entire Korean
population [11,12]. This database includes claims data for medical services and medical costs across the
Korean population and includes clinical information, such as demographics, diagnoses, examination
details, as well as prescription and procedure records for inpatient and outpatient services. We used
the International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM) codes for
diagnostic classification of patients. This study was approved by the Institutional Review Board of
Seoul National University Hospital (E-1808-022-963), and the informed consent was waived by the
review board.
2.1. Study Design
Between January 2010 and April 2018, we identified patients with AF and a history of stroke who
had received ≥1 prescription of any OAC (warfarin or DOACs (rivaroxaban, dabigatran, apixaban,
or edoxaban)). The following were the exclusion criteria in this study: OAC treatment before
1 January 2010, valvular AF, end-stage renal disease, age <20 years, OACs indicated for conditions other
than AF, including deep vein thrombosis, pulmonary embolism, or joint replacement surgery. Finally,
we included 61,568 OAC-naive patients with non-valvular AF who received OACs (warfarin (28,839)
and DOACs (32,729)) for secondary stroke prevention during the study period (Figure S1).
2.2. Covariates
Patient demographics, comorbidities, and details of concomitant medications were retrieved
from the database. Table S1 summarizes the detailed definitions (based on ICD-10-CM codes) of
comorbidities, including hypertension, diabetes mellitus, dyslipidemia, congestive heart failure, prior
myocardial infarction, peripheral artery disease, renal disease, chronic obstructive pulmonary disease,
cancer, and a history of intracranial hemorrhage (ICH) and gastrointestinal bleeding (GIB) [13–15].
The CHA2DS2-VASc score to evaluate stroke risk, the HAS-BLED score (Hypertension (1 point), liver
disease (1 point), renal disease (1 point), stroke history (1 point), bleeding history (1 point), age >65 years
(1 point) and drug (concomitant use of NSAID or antiplatelet agent, 1 point)) to assess bleeding risk
(Table S1), and the Charlson comorbidity index (CCI) that quantifies a patient’s comorbidity burden
was calculated by combining covariates [16–18]. We analyzed the records of concomitant prescriptions
of antiplatelet agents (aspirin or clopidogrel), non-steroidal anti-inflammatory drugs, and proton
pump inhibitors.
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2.3. Study Outcomes and Follow-Up
The first date of index OAC prescription was defined as the index date of follow-up. Patients were
censored at the occurrence of the outcome events, discontinuation of index OAC therapy, or at the
end of the study period (30 April 2018), whichever occurred first. Discontinuation was defined as a
lack of prescription records for OAC 30 days after the last date of index drug prescription. The study
outcomes included recurrent stroke, major bleeding (ICH + hospitalization for GIB), composite outcome
(recurrent stroke + major bleeding), death from each clinical outcome, and all-cause death. A fatal
event was defined as any clinical outcome causing death during the index hospitalization. Detailed
definitions of clinical outcomes are summarized in Table S1.
2.4. Statistical Analyses
We compared the risk of clinical outcomes between (i) warfarin and pooled DOACs and (ii)
warfarin and the individual DOACs using Kaplan–Meier survival analysis with log-rank test and
weighted Cox proportional hazard regression model. Inverse probability of treatment weighting
(IPTW) using propensity scores (PS) was performed to calculate the weights for each comparison [19].
All baseline covariates were subjected to ordinal logistic regression analysis to calculate the PS of being
assigned to a treatment group [18]. We considered the maximum absolute standardized difference
(ASD) of 0.1 (10%) as a negligible difference in baseline characteristics between the comparators [19,20].
After IPTW, incidence rates (IRs) were calculated for all clinical outcomes using weighted event
numbers per 100 person-years. With regard to the absolute measures of clinical benefit, we estimated
absolute risk reduction (ARR) at 1 year follow-up and the number needed to treat (NNT) to prevent
one event for each clinical outcome with DOAC vs. warfarin use. Statistical analyses were performed
using the SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA), and statistical significance was
defined as p < 0.05.
2.5. Subgroup and Sensitivity Analyses
The risk of clinical outcomes between the pooled DOAC and warfarin groups was compared across
subgroups stratified by age, sex, and comorbidities using a multivariable-adjusted Cox proportional
hazard model based on all covariates included for PS calculation. Additionally, we focused on subgroups
of patients with severe, disabling, and recent stroke. Notably, these categories of patients have largely
been excluded or are under-represented in large-scale RCTs. We used the following definitions for these
subgroups: patients with severe stroke were those who required intensive care unit (ICU) admission
for a history of stroke, patients with disabling stroke were those requiring rehabilitation therapy after
stroke-induced disability, and patients with recent stroke were those with a stroke within 6 months
before the index inclusion date.
Additionally, a weighted hazard model with IPTW was used to evaluate clinical outcomes only in
patients receiving regular-dose DOACs (rivaroxaban 20 mg, dabigatran 150 mg, apixaban 5 mg, and
edoxaban 60 mg) at index prescriptions. A significant percentage of Asian patients with AF are often
prescribed reduced doses of DOACs without definitive indication [13,21]. Therefore, we concluded that
sensitivity analysis restricted to patients receiving regular-dose DOACs would be useful to compare
the different types of DOACs in real-world settings. Finally, a sensitivity analysis was performed with
1 year follow-up to equipoise the follow-up period between the DOAC and warfarin groups.
3. Results
3.1. Patients’ Baseline Characteristics
Among the 61,568 patients with non-valvular AF and a history of stroke who received OACs, 28,839
(46.8%), and 32,729 (53.2%) patients received warfarin and DOACs, respectively. Table 1 summarizes
patients’ baseline characteristics. Compared with the warfarin group, patients in the DOAC group
were older with a higher mean CHA2DS2-VASc score but lower mean HAS-BLED and CCI scores.
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The warfarin group showed a higher prevalence of concomitant use of antiplatelet agents but a lower
prevalence of previous GIB.
Table 1. Baseline characteristics of the study population.
Warfarin DOAC
ASD
Rivaroxaban Dabigatran Apixaban Edoxaban
ASD
(n = 28,839) (n = 32,729) (n = 12,311) (n = 6293) (n = 8837) (n = 5288)
Age
Mean ± SD, years 73.1 ± 9.4 75.2 ± 9.1 0.233 75.4 ± 8.8 73.9 ± 9.5 75.9 ± 9.1 75.4 ± 9.0 0.253
<65 years 4757 (16.5) 3974 (12.1) 1389 (11.3) 956 (15.2) 981 (11.1) 648 (12.3)
65–74 years 10,255 (35.6) 9775 (29.9) 3717 (30.2) 2035 (32.3) 2462 (27.9) 1561 (29.5)
75≤ years 13,827 (48.0) 18,980 (58.0) 7205 (58.5) 3302 (52.5) 5394 (61.0) 3079 (58.2)
Male 15,338 (53.2) 16,703 (51.0) 0.043 6037 (49.0) 3453 (54.9) 4427 (50.1) 2786 (52.7) 0.083
CHA2DS2-VASc score
Mean ± SD 5.8 ± 1.5 5.9 ± 1.4 0.123 6.0 ± 1.4 5.8 ± 1.5 6.02 ± 1.41 5.9 ± 1.42 0.143
HAS-BLED score
Mean ± SD 4.2 ± 1.1 4.2 ± 1.1 0.029 4.3 ± 1.1 4.15 ± 1.1 4.24 ± 1.11 4.1 ± 1.11 0.020
≥3 27,534 (95.5) 30,997 (94.7) 11,715 (95.2) 5922 (94.1) 8417 (95.3) 4943 (93.5)
CCI
Mean ± SD 5.2 ± 2.5 4.8 ± 2.5 0.125 4.8 ± 2.5 4.8 ± 2.5 5.0 ± 2.5 4.5 ± 2.5 0.124
≥3 24,466 (84.8) 26,808 (81.9) 10,085 (81.9) 5176 (82.3) 7432 (84.1) 4115 (77.8)
Time lapse from previous stroke
Mean ± SD, years 1.5 ± 1.9 2.6 ± 2.8 2.7 ± 2.7 2.2 ± 2.6 2.6 ± 2.9 3.0 ± 3.0
Median (IQR), years 0.6 (0.1–2.5) 1.4 (0.1–4.7) 1.7 (0.2–4.8) 0.9 (0.1–3.9) 1.2 (0.1–4.7) 2.0 (0.1–5.4)
Hypertension 26,072 (90.4) 29,265 (89.4) 0.033 11,056 (89.8) 5578 (88.6) 7945 (89.9) 4686 (88.6) 0.020
Diabetes mellitus 9869 (34.2) 10,467 (32.0) 0.048 3885 (31.6) 1971 (31.3) 3036 (34.4) 1575 (29.8) 0.057
Dyslipidemia 18,774 (65.1) 21,899 (66.9) 0.038 7890 (64.1) 4484 (71.3) 6062 (68.6) 3463 (65.5) 0.021
Congestive heart failure 11,972 (41.5) 14,780 (45.2) 0.074 5389 (43.8) 2751 (43.7) 4175 (47.2) 2465 (46.6) 0.046
Myocardial infarction 1836 (6.4) 1829 (5.6) 0.033 705 (5.7) 325 (5.2) 553 (6.3) 246 (4.7) 0.027
Peripheral arterial disease 7668 (26.6) 9075 (27.7) 0.026 3510 (28.5) 1816 (28.9) 2269 (25.7) 1480 (28.0) 0.043
COPD 4080 (14.2) 3994 (12.2) 0.058 1620 (13.2) 687 (10.9) 1158 (13.1) 529(10) 0.029
Cancer 2000 (6.9) 2541 (7.8) 0.032 970 (7.9) 449 (7.1) 763 (8.6) 359 (6.8) 0.036
Previous Intracranial hemorrhage 1530 (5.3) 1959 (6.0) 0.029 719 (5.8) 404 (6.4) 548 (6.2) 288 (5.5) 0.023
Previous gastrointestinal
bleeding 5039 (17.5) 7678 (23.5) 0.149 2878 (23.4) 1396 (22.2) 2117 (24.0) 1287 (24.3) 0.147
Antiplatelets 0.440 0.431
No antiplatelets 12,731 (44.2) 21,454 (65.6) 8016 (65.1) 4097 (65.1) 5705 (64.6) 3636 (68.8)
Aspirin only 7990 (27.7) 5183 (15.8) 2006 (16.3) 1021 (16.2) 1410 (16.0) 746 (14.1)
Clopidogrel only 2816 (9.8) 3209 (9.8) 1199 (9.7) 621 (9.9) 870 (9.8) 519 (9.8)
Dual antiplatelets 5302 (18.4) 2883 (8.8) 1090 (8.9) 554 (8.8) 852 (9.6) 387 (7.3)
NSAID 13,940 (48.3) 14,321 (43.8) 0.092 5799 (47.1) 2902 (46.1) 3617 (40.9) 2003 (37.9) 0.025
Proton pump inhibitors 9090 (31.5) 12,073 (36.9) 0.113 4429 (36.0) 2516 (40.0) 3336 (37.8) 1792 (33.9) 0.094
The numbers are presented as the mean ± standard deviation, median (IQR), or numbers (percentage) otherwise
mentioned. Abbreviation: ASD, absolute standardized difference; CCI, charlson comorbidity index; COPD, chronic
obstructive pulmonary disease; DOAC, direct oral anticoagulant; IQR, interquartile range; NSAID, non-steroidal
anti-inflammatory drug; SD, standard deviation. HAS-BLED score: Hypertension (1 point), liver disease (1 point),
renal disease (1 point), stroke history (1 point), bleeding history (1 point), age >65 years (1 point) and drug
(concomitant use of NSAID or antiplatelet agent, 1 point).
With regard to the types of DOACs administered, 12,311 (37.6%), 6293 (19.1%), 8837 (27.0%),
and 5288 (16.2%) patients received rivaroxaban, dabigatran, apixaban, and edoxaban, respectively.
All covariates were well balanced after IPTW (ASDs for all covariates ≤0.1) (Table S2; Figure S2) and
the mean age was 74 years with a mean CHA2DS2-VASc score of 5.9.
3.2. Recurrent Stroke, Major Bleeding, Composite Outcome, Death from Each Clinical Outcome,
and All-Cause Death
We observed that during a median follow-up of 0.7 years (interquartile range 0.2–1.9 years),
recurrent stroke, major bleeding, and composite outcome occurred in 5.7% (n = 3507), 3.1% (n = 1905),
and 8.4% (n = 5189) of patients, respectively. Table 2 shows the weighted hazard ratios (HRs) for
clinical outcomes after IPTW. Compared with warfarin, DOAC use was associated with a lower risk of
recurrent stroke (HR 0.67, 95% confidence interval (CI) 0.62–0.72), major bleeding (HR 0.73, 95% CI
0.66–0.80), and composite outcome (HR 0.69, 95% CI 0.65–0.73). DOAC use was also associated with a
lower risk of fatal recurrent stroke (HR 0.69, 95% CI 0.59–0.79), fatal major bleeding (HR 0.50, 95% CI
0.37–0.68), fatal composite outcome (HR 0.65, 95% CI 0.57–0.74), and all-cause death (HR 0.84, 95% CI
0.80–0.89).
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Figure S3 shows the weighted Kaplan–Meier curves for clinical outcomes in the DOAC and
warfarin groups. DOAC use was associated with a better event-free survival rate with regard to all
clinical outcomes.
Table 2. The cumulative risk of clinical outcomes according to antithrombotic therapy.
Outcome
Warfarin DOAC
*HR (95% CI) p-Value
Event (IR) Event (IR)
Recurrent stroke 2294 (4.9) 1184 (4.2) 0.67 (0.62–0.72) <0.001
Major bleeding 1263 (2.6) 633 (2.2) 0.73 (0.66–0.80) <0.001
Composite outcome
(Recurrent stroke + major bleeding) 3387 (7.4) 1765 (6.4) 0.69 (0.65–0.73) <0.001
Fatal recurrent stroke 501 (1.0) 307 (1.1) 0.69 (0.59–0.79) <0.001
Fatal major bleeding 188 (0.4) 60 (0.2) 0.50 (0.37–0.68) <0.001
Fatal composite outcome 684 (1.4) 366 (1.3) 0.65 (0.57–0.74) <0.001
All-cause death 3169 (6.4) 2092 (7.4) 0.84 (0.80–0.89) <0.001
* Inverse probability of treatment weighting (IPTW) adjustment. Abbreviation: CI, confidence interval; DOAC,
direct oral anticoagulant; HR, hazard ratio; IR, incidence rate.
3.3. Comparison between Warfarin and Individual Non-Vitamin K Oral Anticoagulants
Figure 1 shows the weighted HRs for clinical outcomes in the warfarin and the four DOAC groups.
Compared with warfarin, all four DOACs showed a lower risk of clinical outcomes. With regard
to major bleeding and the composite outcome, compared to other DOACs, edoxaban showed the
lowest risk (HR 0.54, 95% CI 0.42–0.70 for major bleeding and HR 0.62, 95% CI 0.54–0.71 for composite
outcome). Compared to warfarin, all four DOACs were associated with a lower risk of death from each
clinical outcome and all-cause death. Among the four DOACs, edoxaban showed the lowest risk of
fatal recurrent stroke (HR 0.43, 95% CI 0.29–0.62), fatal composite outcome (HR 0.44, 95% CI 0.31–0.60),
and all-cause death (HR 0.72, 95% CI 0.63–0.81). Weighted Kaplan–Meier curves for clinical outcomes
of the four DOACs are shown in Figure S4.
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3.4. The Number Needed to Treat for Clinical Outcomes in the Non-Vitamin K Oral Anticoagulant and
Warfarin Groups
Table 3 shows the 1 year ARR and NNT values for (i) pooled DOACs and, (ii) each type of DOAC
compared with warfarin. Among the pooled DOACs, the NNT values to prevent one recurrent stroke
and one composite event were 65 and 48, respectively. The NNT for preventing one death with the use
of DOACs was 94.
Among the four types of DOACs, compared with warfarin, edoxaban showed the lowest NNT
with regard to all clinical outcomes except major bleeding. The NNT to prevent one composite outcome
event was 35 in patients receiving edoxaban.
Table 3. The 1 year ARR and NNT with pooled DOACs and each DOAC compared to warfarin.
Outcome
Pooled DOAC Rivaroxaban Dabigatran Apixaban Edoxaban
1 year
ARR NNT
1 year
ARR NNT
1 year
ARR NNT
1 year
ARR NNT
1 year
ARR NNT
Recurrent stroke 1.5 65 1.7 60 1.3 78 1.0 100 2.3 44
Major bleeding 0.7 142 0.4 284 0.8 119 1.0 98 0.7 135
Composite outcome (Recurrent
stroke + major bleeding) 2.1 48 1.9 54 2.0 49 1.8 54 2.9 35
All-cause death 1.1 94 0.6 180 1.3 77 0.6 179 2.7 38
Fatal composite outcome 0.5 190 0.6 175 0.4 271 0.3 287 0.9 118
Abbreviation: ARR, absolute risk reduction; DOAC, direct oral anticoagulant; NNT, the number needed to treat.
3.5. Subgroup Analyses
The crude IRs of clinical outcomes among the subgroups are summarized in Table S3.
Subgroup analysis for age, sex, baseline CHA2DS2-VASc, HAS-BLED, and CCI scores, diabetes
mellitus, hypertension, chronic kidney disease, and heart failure were consistent with our main results,
although significant interactions were observed with regard to hypertension (ischemic stroke and
composite outcome), chronic kidney disease (composite outcome), and CCI (recurrent stroke, major
bleeding, composite outcome, and all-cause death) (Figure S5). DOACs showed a consistent trend of
risk reduction with regard to all clinical outcomes across all subgroups.
3.6. Severe, Disabling, and Recent Stroke
Figure 2 shows the HRs for clinical outcomes among subgroups of patients with recent stroke
(n = 6499), patients with a prior stroke-related ICU admission (n = 13,632), and patients requiring
rehabilitation therapy secondary to disabling stroke (n = 5291). Compared to warfarin, DOACs showed
a consistent trend of risk reduction with regard to all clinical outcomes across all three subgroups.
3.7. Sensitivity Analysis
Sensitivity analysis using a multivariable-adjusted Cox proportional hazard model showed findings
similar to our main results with regard to pooled DOACs (Table S4) and the four types of DOACs
individually (Table S5). Among patients administered DOACs, 12,073 (36.9%) received regular-dose
DOACs (Table S6). Compared with those administered warfarin, patients who received regular-dose
DOACs showed significantly improved clinical outcomes (Table S7; Figure S6). Compared with warfarin,
the clinical improvement observed with regular doses of the four types of DOACs was similar to our
main results except with regard to fatal major bleeding because of the relatively small numbers of events
(Figure S7; Figure S8). Among the four types of DOACs, edoxaban was associated with the lowest risk
of most clinical outcomes. Sensitivity analysis with 1 year follow-up showed that the HRs for all clinical
outcomes followed trends that resembled those observed in our main analysis (Figure S9).
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4. Discussion
In this large nationwide population-based study, we investigated the effectiveness and safety
of DOACs compared with that of warfarin for secondary prevention among Asian patients with
non-valvular AF. This study highlights the following findings: (1) Compared to warfarin, DOAC use
was associated with lower risks of recurrent stroke, major bleeding, and composite outcome. (2) DOAC
use was also associated with lower risks of fatal recurrent stroke, fatal major bleeding, fatal composite
outcome, and all-cause death. (3) Consistent trends in effectiveness and safety were observed across all
four types of DOACs and regular-dose DOACs. (4) Following subgroup analysis, DOACs showed
better clinical outcomes in patients with severe, disabling, and recent stroke.
To our knowledge, this is the largest study that investigated patients with AF and a history of
stroke to compare the effectiveness and safety of DOACs with that of warfarin, particularly focusing
on the aforementioned subgroups that have been under-represented in previous clinical trials.
A recent meta-analysis of four major clinical trials reported that compared to warfarin, DOACs
showed a significantly lower risk of stroke or systemic embolism in patients with AF and a history of
stroke [22]. Several studies using population-based claims databases have investigated the effectiveness
and safety of different types of DOACs compared with that of warfarin in patients with AF and a
history of stroke [9,23–25]. A Danish nationwide cohort study reported that the risks of ischemic stroke
or systemic embolism associated with apixaban, dabigatran, and rivaroxaban were comparable to
those associated with warfarin [23]. With regard to safety outcomes, dabigatran was associated with a
lower risk of major bleeding, whereas the risk profile of apixaban and rivaroxaban was comparable
with that of warfarin. Another study using the MarketScan claims data reported that rivaroxaban
showed a lower risk of composite endpoint of ischemic stroke or ICH, whereas the risk profile of
apixaban and dabigatran was comparable to that of warfarin [9]. Notably, both studies included a
relatively small number of patients with AF and a history of stroke; therefore, these studies were of
low statistical power (Danish study (n = 9463) and US MarketScan claims study (n = 9684)).
The clinical benefit of DOACs in risk reduction of fatal clinical outcomes (fatal recurrent stroke,
fatal major bleeding, and death from composite outcome) observed in our study was consistent with that
reported by previous RCTs [5–8]. We estimated the ARR and NNT for each clinical outcome associated
with DOACs compared to warfarin to calculate the expected absolute benefit in individual patients.
The NNT to prevent one recurrent stroke event with the use of DOACs was 65. With regard to safety
outcomes, the NNT to prevent one major bleeding event with the use of DOACs was 142, and compared
with warfarin, DOAC use resulted in a more favorable NNT value of 48 to prevent one composite
outcome. Increasing numbers of patients with AF and a history of stroke are being encountered
in clinical practice; therefore, our results emphasize the importance of DOAC use considering their
cost-effectiveness for secondary stroke prevention in patients with AF [26].
A recent study using Taiwan’s National Health Insurance Research Database investigated patients
with AF and a history of stroke and reported that all four types of DOACs were associated with a
lower risk of ischemic stroke or systemic embolism; edoxaban use led to the highest risk reduction in
these patients [24]. With regard to safety outcomes, all four types of DOACs showed similar efficacy in
reducing the risk for major bleeding; however, edoxaban and apixaban were associated with greater
risk reduction than dabigatran and rivaroxaban.
Previous pivotal RCTs excluded patients with AF and a history of stroke within 1–2 weeks
preceding randomization and those with severe/disabling stroke. Therefore, data describing the clinical
benefit of DOACs vs. warfarin in this population are limited. A strength of our study is the large-sized
real-world cohort comprising heterogeneous subgroups that may have been under-represented in
RCTs. Therefore, we performed subgroup analyses to determine whether the benefits of DOACs were
consistent across all patient categories (those with recent stroke [<6 months] and those with severe
and disabling stroke). We observed that compared to warfarin, DOACs showed similar trends in
reducing risks of clinical outcomes across all subgroups, although the IR of the fatal clinical outcomes
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was relatively low. Our results support DOAC use in this patient population based on their proven
clinical benefits.
The issue of appropriate dosing for DOACs in real-world clinical practice is particularly important
where insufficient anticoagulation for stroke prevention is prevalent [21]. A recent meta-analysis
reported that compared to warfarin, regular-dose DOACs showed a significantly lower risk of
ischemic stroke with comparable risks of major bleeding for secondary prevention in cases of AF [27].
Several observational studies indicate that inappropriate prescriptions of low-dose DOACs with poor
adherence to label- or guideline recommendations (particularly with apixaban) increase the risk of
thromboembolic events without reducing bleeding events [24,25]. In the current study, approximately
one-third (36.9%) of all patients received regular-dose DOACs and compared to warfarin, regular-dose
DOACs were consistently associated with better clinical outcomes and lower risks of recurrent stroke,
major bleeding, and composite outcome. In line with previous studies, our results indicate that it is
important to prescribe the label- or guideline-recommended dose of DOACs for effective secondary
stroke prevention in patients with AF in real-world practice.
Study Limitations
The following are the limitations of this study that should be addressed. (1) This retrospective
study utilized information obtained from a nationwide claims database. Although we used IPTW
to adjust for baseline differences between treatment groups, there might be uncaptured residual
confounders that could affect treatment effects. (2) Laboratory investigations, such as the international
normalized ratio (based on the results of prothrombin time), are not included in the NHIS database;
therefore, the quality of anticoagulation in the warfarin group could not be confirmed. Notably, the
quality of anticoagulation in Korean patients with ischemic stroke and AF was shown to be low, with
a mean time in therapeutic range of 49% [28]. Our results need careful interpretation considering
inadequate anticoagulation in Asian patients receiving warfarin [29]. (3) We could not evaluate the
actual drug adherence to OACs (warfarin and DOACs) in individual patients, which is an inherent
limitation of any real-world study. (4) We investigated the clinical benefits of individual DOACs
compared with those of warfarin; however, the current study was not focused on direct comparisons
between the different types of DOACs. (5) The NHIS database does not contain data for body weight
and creatinine clearance; therefore, we could not assess the appropriateness of DOAC dosing used
for each patient. (6) Among the patients with DOACs, 63.1% of them received reduced dose DOACs
which could inflate the clinical benefit of DOACs compared to warfarin. However, we performed
additional sensitivity analysis restricted to patients who received regular dose DOACs and found a
consistent trend for the effectiveness and safety of DOACs compared to warfarin even after excluding
those with reduced dose DOACs.
5. Conclusions
DOACs were associated with significantly lower risks of recurrent stroke, major bleeding,
composite clinical outcome, and mortality in patients with AF and a history of stroke. The results were
consistent across different types and doses of DOACs and across subgroups of patients with recent,
severe, and disabling stroke.
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